1 active not recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
Follow Placebo for Olaparib: new trials by email Literature Review of Placebo for Olaparib trials Research Report on Placebo for Olaparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) Durvalumab, Placebo for Olaparib, Olaparib - Non-small Cell Lung Cancer NSCLC | Phase 2 | Active not recruiting | AstraZeneca | 401 | 2018-12-21 | 2026-09-11 |
AstraZeneca (1)
Belgium (1) · Hungary (1) · India (1) · Japan (1) · Mexico (1) · Netherlands (1) · Poland (1) · Russia (1) · South Korea (1) · Ukraine (1) · United Kingdom (1) · United States (1)
Myung-Ju Ahn, MD (1)
2018 (1)